Literature DB >> 1525574

Why the NOSPECS classification of Graves' eye disease should be abandoned, with suggestions for the characterization of this disease.

B R Frueh1.   

Abstract

The NOSPECS classification of Graves' eye disease is inadequate for a number of reasons: (a) poor characterization of the condition with no indication of disease activity, marked underrepresentation of eyelid position, and overrepresentation of corneal problems, (b) it represents neither a continuous nor stepladder progression of disease as the numbered classification would suggest, (c) parts of it are subjective, and (d) the gradings of classes 3, 5, and 6 are poor. Graves' eye disease should be characterized rather than classified, using objective clinical assessments of optic nerve function, proptosis, ocular motility, and eyelid position. It is recommended that a multicenter clinical trial be done to determine the significance of different values and changes in values for each assessment. Disease activity is to be defined by the clinical trial in terms of changes of the four assessments as a function of time. This should produce a simple characterization that would create an image of the patient's eye problems for a knowledgeable physician and be sufficient to guide decisions on whether currently accepted surgical therapies are advisable. Data from the clinical trial would enable the characterization to predict the likelihood of success of various immunosuppressive therapies.

Entities:  

Mesh:

Year:  1992        PMID: 1525574     DOI: 10.1089/thy.1992.2.85

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

1.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.

Authors:  Raymond S Douglas; Angelo Tsirbas; Mark Gordon; Diana Lee; Nicole Khadavi; Helene Chokron Garneau; Robert A Goldberg; Kenneth Cahill; Peter J Dolman; Victor Elner; Steve Feldon; Mark Lucarelli; Jimmy Uddin; Michael Kazim; Terry J Smith; Dinesh Khanna
Journal:  Arch Ophthalmol       Date:  2009-09

3.  The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy.

Authors:  M N Gerding; M F Prummel; R Kalmann; L Koornneef; W M Wiersinga
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

4.  Quality of life in patients with Graves ophthalmopathy.

Authors:  R Patrick Yeatts
Journal:  Trans Am Ophthalmol Soc       Date:  2005

5.  Clinical outcomes of radiotherapy as initial local therapy for Graves' ophthalmopathy and predictors of the need for post-radiotherapy decompressive surgery.

Authors:  Roshan S Prabhu; Lang Liebman; Ted Wojno; Brent Hayek; William A Hall; Ian Crocker
Journal:  Radiat Oncol       Date:  2012-06-19       Impact factor: 3.481

6.  The efficacy of intensity modulated radiation therapy in treating thyroid-associated ophthalmopathy and predictive factors for treatment response.

Authors:  Yong-Jiang Li; Yong Luo; Xiao-Qi Xie; Wei-Min He; Cheng Yi; Ping Li; Feng Wang
Journal:  Sci Rep       Date:  2017-12-13       Impact factor: 4.379

7.  Longitudinal association of thyroid-stimulating immunoglobulin levels with clinical characteristics in thyroid eye disease.

Authors:  JaeSang Ko; Koung Hoon Kook; Jin Sook Yoon; Kyung In Woo; Jae Wook Yang
Journal:  BMJ Open       Date:  2022-06-21       Impact factor: 3.006

8.  Clinical outcomes of graves' ophthalmopathy treated with intensity modulated radiation therapy.

Authors:  Yong-Jiang Li; Yong Luo; Wei-Min He; Ping Li; Feng Wang
Journal:  Radiat Oncol       Date:  2017-11-06       Impact factor: 3.481

9.  Clinical outcomes of hypofractionated radiotherapy for thyroid-associated ophthalmopathy.

Authors:  Sang Min Lee; Jung Ho Im; Hyun Soo Shin; Helen Lew
Journal:  BJR Open       Date:  2020-09-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.